Retia Medical

Retia Medical is an innovative digital health company that develops accurate and affordable advanced hemodynamic solutions designed to inform care protocols, improve outcomes and prevent complications for high-risk patients. The company is headquartered in White Plains, New York, in the United States, and was founded by Marc Zemel, who serves as Co-Founder and CEO. Retia positions itself around a simple but ambitious idea: patients often begin to deteriorate before changes appear in standard vital signs, and reliable cardiovascular intelligence should be available wherever care is delivered, not only in specialized units with expensive hardware. The company's core offering is the Argos® Cardiac Output (CO) Monitor, which enables advanced hemodynamic monitoring for high-risk patients. Its proprietary technology is intended to ensure patient safety with real-time clinical decision support using advanced algorithms, allowing clinicians to implement data-driven care protocols. Retia states that the Argos algorithm is reliable in shock and arrhythmia and requires no disposable sensors, addressing common limitations of traditional monitoring systems that can be invasive, unreliable in unstable patients, and dependent on costly hardware and disposables. Retia has extended its technology into an enterprise software layer called Argos Infinity™. Argos Infinity runs on top of existing monitoring and tele-ICU platforms, transforming real-time physiologic data into enterprise-wide cardiovascular insight. It uses the identical Multi-Beat Analysis (MBA™) algorithm validated in the FDA-cleared Argos® Cardiac Output Monitor and extends that intelligence across beds, units and health systems. The platform is designed for digital care environments, including tele-ICUs and digital operating rooms, and can deliver cardiovascular parameters and trends to bedside displays, central stations, tele-ICU dashboards, authorized mobile devices and EMR systems. According to the company's website, its technology has been installed in 75 hospitals and is supported by 14 clinical studies. Retia emphasizes earlier insight and safer care, noting that in cardiac surgery patients nearly 70% of low cardiac index time occurs while blood pressure remains normal, and that delayed recognition drives ICU escalation, organ injury and hospital harms such as acute kidney injury. The company also points to a reimbursement tailwind: beginning in 2027, acute kidney injury will be tracked as a hospital harm tied to reimbursement. Retia Medical describes itself as aiming to transform the practice of critical care by integrating scientific and computational excellence with a passion for improving patient care through medical and scientific innovation. It has built a team of industry-leading technical experts and clinician advisors, and it markets its solutions to leading health systems. The company operates primarily in the United States and remains a private, venture-stage medical technology business.

Retia Medical was founded as a digital health company focused on advanced hemodynamic monitoring. The company is headquartered in White Plains, New York, in the United States, and is led by Co-Founder and CEO Marc Zemel, a serial entrepreneur with experience at Fortune 500 companies and startups in the medical device, imaging and capital equipment markets. Retia states that it was founded to remove barriers that limit reliable cardiovascular monitoring to select beds and specialized units, and to make cardiovascular intelligence available wherever care is delivered. The company's foundational product is the Argos® Cardiac Output (CO) Monitor, which enables advanced hemodynamic monitoring for high-risk patients. Its proprietary technology is designed to provide real-time clinical decision support using advanced algorithms and to allow clinicians to implement data-driven care protocols. Retia emphasizes that the Argos algorithm is reliable in shock and arrhythmia and requires no disposable sensors, contrasting it with traditional monitoring systems that can be invasive, unreliable in unstable patients, and dependent on expensive hardware and disposables. Retia subsequently developed Argos Infinity™, an enterprise cardiovascular surveillance platform that runs on top of existing monitoring and tele-ICU platforms. Argos Infinity uses the identical Multi-Beat Analysis (MBA™) algorithm validated in the FDA-cleared Argos® Cardiac Output Monitor and extends that intelligence across beds, units and health systems. It is built for digital care environments, including tele-ICUs and digital operating rooms, and can deliver cardiovascular parameters and trends to bedside displays, central stations, tele-ICU dashboards, authorized mobile devices and EMR systems. According to the company's website, its technology has been installed in 75 hospitals and is supported by 14 clinical studies. Retia has built a team of industry-leading technical experts and clinician advisors to support its growth. The company markets its solutions to leading health systems and operates primarily in the United States. It remains a private company.

• Retia Medical founded as a digital health company focused on advanced hemodynamic monitoring.

• Argos® Cardiac Output Monitor developed with proprietary Multi-Beat Analysis (MBA™) algorithm.

• Argos Infinity™ enterprise cardiovascular surveillance platform introduced, extending the MBA™ algorithm across beds, units and health systems.

• Company reports 75 hospitals installed and 14 clinical studies supporting its technology.

Accurate, simple, low-cost cardiovascular monitoring and intelligence that deploys across bedside, enterprise and virtual care settings without disposable sensors.

• Argos® Cardiac Output (CO) Monitor

  Enables advanced hemodynamic monitoring for high-risk patients. Its proprietary technology ensures patient safety with real-time clinical decision support using advanced algorithms and allows clinicians to implement data-driven care protocols. Reliable in shock and arrhythmia, with no disposable sensors.

• Argos Infinity™

  Enterprise cardiovascular surveillance software that runs on top of existing monitoring and tele-ICU platforms, transforming real-time physiologic data into enterprise-wide cardiovascular insight. Uses the identical Multi-Beat Analysis (MBA™) algorithm validated in the FDA-cleared Argos® Cardiac Output Monitor. Designed for tele-ICUs and digital ORs, delivering parameters and trends to bedside displays, central stations, tele-ICU dashboards, mobile devices and EMR systems.

• 2022.02.02

  Reported2022.02.02

  Retia Medical appoints James Ferreira as VP of U.S. Sales[6]Retia Medical任命James Ferreira为美国销售副总裁prnewswire.com

  Retia Medical announced James Ferreira as its Vice President of U.S. Sales. His responsibilities include sales-team leadership and efforts to expand adoption of the company's monitors.

Read more

1. 1Accurate, Simple, Low-Cost CO Monitoring | Retia Medicalretiamedical.com
2. 2Hemodynamic Solutions that Transform Patient Care - Retia Medicalretiamedical.com
3. 3Careers - Retia Medicalretiamedical.com
4. 4Argos Infinity - Retia Medicalretiamedical.com
5. 5Retia Medical (United States) - Wikidatawikidata.org
6. 6Retia Medical任命James Ferreira为美国销售副总裁prnewswire.com